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Allele-specific Differences in Activity of a Novel Cannabinoid
Receptor 1 (CNR1) Gene Intronic Enhancer in Hypothalamus,
Dorsal Root Ganglia, and Hippocampus*
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Background: Intron 2 of CNR1 gene contains multiple disease-associated SNPs.
Results: Allelic variants of a novel enhancer in CNR1 intron 2 affect its MAPK response in hypothalamus and hippocampus.
Conclusion: Alleles of enhancer may be functionally linked to obesity and addictive behavior.
Significance: Understanding the effects of CNR1 polymorphisms on gene regulation will accelerate understanding of human
disease.
Polymorphisms within intron 2 of the CNR1 gene, which
encodes cannabinoid receptor 1 (CB1), have been associated
with addiction, obesity, and brain volume deficits. We used
comparative genomics to identify a polymorphic (rs9444584-
C/T) sequence (ECR1) in intron 2 of the CNR1 gene that had
been conserved for 310 million years. The C-allele of ECR1
(ECR1(C)) acted as an enhancer in hypothalamic anddorsal root
ganglia cells and responded to MAPK activation through the
MEKK pathway but not in hippocampal cells. However,
ECR1(T)was significantlymore active in hypothalamic and dor-
sal root ganglia cells but, significantly, and in contrast to
ECR1(C), was highly active in hippocampal cells where it also
responded strongly to activation of MAPK. Intriguingly,
rs9444584 is in strong linkage disequilibrium with two other
SNPs (rs9450898 (r2  0.841) and rs2023239 (r2  0.920)) that
have been associated with addiction, obesity (rs2023239), and
reduced fronto-temporal white matter volumes in schizophre-
nia patients as a result of cannabis misuse (rs9450898). Consid-
ering their high linkage disequilibrium and the increased
response of ECR1(T) to MAPK signaling when compared with
ECR1(C), it is possible that the functional effects of the different
alleles of rs9444584may play a role in the conditions associated
with rs9450898 and rs2023239. Further analysis of the different
alleles of ECR1may lead to a greater understanding of the role of
CNR1 gene misregulation in these conditions as well as chronic
inflammatory pain.
The cannabinoid receptor 1 (CB1)5 is a Gi/Go-protein-cou-
pled receptor whose endogenous ligands include anandamide
and 2-arachidonoyl glycerol (1, 2). CB1 is strongly expressed in
a number of different regions of the central nervous system
such as the hypothalamus, hippocampus, and dorsal root gan-
glia (DRG) where it is known to play a role in modulating appe-
tite (3–5), cognition and memory (6–8), and inflammatory
pain, respectively (9).
Because of the role of CB1 in these processes, there have been
a number of genetic studies linking polymorphisms in and
around the CNR1 gene to conditions such as cognitive decline,
drug addiction, schizophrenia, obesity, and inflammatory pain.
For example, one polymorphism that occurs within intron 2 of
the CNR1 gene, rs2023239, has been associated with impulsiv-
ity (10), obesity (11), nicotine dependence (12), alcoholism (13),
cannabiswithdrawal and dependence (14, 15), substance addic-
tion, and resistance to anti-depressive treatment (16). A second
CNR1 intron 2 polymorphism, rs9450898, was associated with
smaller fronto-temporal white matter volumes and greater
schizophrenia risk due to cannabis misuse (17). Intriguingly,
rs9450898 and rs2023239 are separated by only 2 kb and are in
strong linkage disequilibrium (LD; r2  0.915). However, no
mechanism has yet been discovered to explain the symptoms
associated with rs9450898 or rs2023239.
We explored the hypothesis that polymorphic variation
within CNR1 intron 2 might change the activity of unidentified
cis-regulatory regions.We used comparative genomics to iden-
tify highly conserved functional elements withinCNR1 intron 2
that might represent a cis-regulatory region. We then used
molecular biology, primary cell culture, and pharmacology to
isolate these sequences and to assess the effects of different
alleles on the activity, tissue specificity, and signal transduction
response of these polymorphic cis-regulatory regions. The sig-
nificances of these results are discussed in the context of the
role of the CB1 receptor in the hypothalamus, hippocampus,
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and dorsal root ganglia, and consequences for disease suscepti-
bility are explored.
EXPERIMENTAL PROCEDURES
Bioinformatic Analysis—17-species vertebrate genome com-
parisons and detection of linkage disequilibrium was carried
out using the Human (Homo sapiens) Genome Browser Gate-
way through theUCSCGenome Browser (see Fig. 1). Detection
of transcription factor binding consensus sequences was car-
ried out using the web-based program MATCH through BIO-
BASE (18). Prediction of the effects of rs9444584 on transcrip-
tion factor-DNA binding was carried out using the newly
developed RegSNP website. Linkage disequilibrium between
SNPs was quantified using SNAP LD.
Plasmid Constructs—ECR1 was amplified from placental
human DNA using the Expand high fidelity PCR kit and the
following primers, ECR1F-TAAGCTAGGGCATGGGTGTG
and ECR1R-TAGTGGAGAGGCAGGTTTGC (657 bp), as
described in the manufacturer’s instructions (Roche Applied
Science), and cloned into pGEM-T Easy as described (Strat-
agene) to form pECR1(C)-GEMT-Easy. The correct amplifica-
tion and orientation of ECR1(C) within the pGEM-T Easy vec-
tor was checked with restriction enzyme digestion and
sequencing. The pLuc plasmid (renamed for clarity from
pTAL-Luc, Clontech, see Fig. 2D) contains a herpes simplex
virus-thymidine kinase minimal promoter that has a low tran-
scriptional activity. pECR1(C) was produced by removing the
ECR1(C) fragment from pECR1(C)-GEMT-Easy using NheI
and SmaI and cloning into the ApaI (made blunt-ended using
Klenow) and SpeI sites of the pLuc vector (see Fig. 2D).
pECR1(T) was recreated by mutating the ECR1(C) sequence
within pGEM-T Easy vector using QuikChange II site-directed
mutagenesis kit (Stratagene) and the following primers,
ECR1F-GAGAGTTCATTACTAATATGGCTTAGG and
ECR1RCCTAAGCCATATTAGTAATGAACTCTC, to pro-
duce ECR1(T). ECR1(T) was then cloned into pLuc in the same
way as pECR1(C) to produce pECR1(T) (see Fig. 2D).
Primary Cell Culture—1–3-day-old rat neonates were
humanely euthanized in accordance with current United King-
dom Home Office schedule 1 guidelines, and the hippocampal
or hypothalamic regionswere immediately dissected out in into
DMEM/F12 (Invitrogen) under sterile conditions. The tissue
was chopped into fine pieces and placed in 2ml of trypsin/0.5 M
EDTA for 6 min, and tissues were dissected as described previ-
ously (19). The tissue was then dissociated by gentle trituration
in DMEM/F12 medium with a fire-polished glass pipette
(1-mmdiameter) and centrifuged at 5000 rpm for 2min. This
process was repeated, and cells were counted on a hemocytom-
eter and plated out onto 24-well plates at a density of 5 104/
cm2. Cultures were allowed to recover for 3 days at 37 °C in
medium consisting of 90% DMEM/F12 media, 10% dialyzed
FCSwith penicillin/streptomycin until themajority of cells had
formed neurite outgrowths. DRG cells were recovered and cul-
tured as described previously (19, 20).
Cell Transfection—Magnetic transfection of plasmid con-
structs into primary lines was performed according to theman-
ufacturer’s instructions (OZ Biosciences). In summary, Neuro-
Mag reagent was added to the plasmid preparation in the ratio
of 3 l/1 g of plasmid DNA in the medium. The DNA-media-
NeuroMag solution was mixed and incubated at room temper-
ature for 15 min. The DNA-media-NeuroMag solution was
then added to previously prepared single cell cultures in 24-well
plates and incubated on amagnetofectionmagnetic plate for 15
min in a cell culture incubator at 37 °C and 5% CO2. Following
transfection, cells were treated with 10 M angiotensin II (Toc-
ris) or angiotensin II plus aMEK kinase inhibitor (U0216, 1M,
Tocris) a JNK II inhibitor (SP600125, 50 nM, Tocris), or a p38
kinase inhibitor (SB202190, 10 M, Tocris) for 24 h.
Dual-Luciferase Assay—24 h after transfection and agonist/
antagonist treatments, Dual-Luciferase assays were performed
on lysates made from primary cell cultures according to the
manufacturer’s instructions (Promega). The Dual-Luciferase
assay analysis was carried out on a GloMax 96microplate lumi-
nometer (Promega) using 20 l of cell lysate per well of a white
96-well plate.
Statistical Analysis—All experiments were repeated a mini-
mum of three times on separate dates using separate groups of
animals (n 3). Two-tailed Student’s t tests or analysis of vari-
ance were used, where appropriate, to test the significance of
data derived from primary cell cultures. Statistical analysis was
done using Microsoft Excel.
RESULTS
A Highly Conserved Region within Intron 2 Contains an SNP
in Strong LD with rs9450898 and rs2023239—Many novel cis-
regulatory elements display high levels of evolutionary conser-
vation because of their critical role in modulating the tissue-
specific expression of genes (19–20, 22–30). Because intron 2
of the CNR1 gene contained a number of disease-associated
SNPs (10–17), we asked whether intron 2 contained functional
sequences such as cis-regulatory elements that could direct tis-
sue-specific gene expression. Using comparative genomics, we
identified a 402-bp region of high conservation (chr6:
88919055–88919457) that had been conserved from the com-
mon ancestor of birds and humans (310 million years; Figs. 1A
and 2A). Intriguingly, we found that this sequence contained a
polymorphism (rs9444584; C/T) that was in strong LD with
rs9450898 and rs2023239 (r2  0.815 and 0.920, respectively),
which have been associated with different conditions in multi-
ple association analyses (10–17). The two alleles of this 402-bp
region of DNA were called ECR1(C) and ECR1(T).
Examination of the population diversity of these alleles dem-
onstrated that in Eurasian populations, the T allele was com-
paratively rare and was only found in 13–20% of the alleles
within the population (Fig. 2B). However, in sub-Saharan
Africa, the frequency between C and T alleles was nearly equal
(47 and 53%, respectively, Fig. 2B). Predictive software pro-
grams (Match and Transfac) were used to show the presence of
androgen receptor (AR), CCAAT enhancer-binding protein
(C/EBP), transcription factor II A (TFII-A), and activator pro-
tein-1 (AP1) binding sites within ECR1 (Fig. 2A). Using our
newly developed RegSNP program, wewere able to predict that
ECR1(C) would have relatively low affinity for the AP-1 tran-
scription factor (p-core binding 0.448), whereas the ECR1(T)
allele would have a significantly increased affinity (p-core bind-
ing 0.736).
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FIGURE 1. rs9444584 is in strong LD with rs92023230 and rs9450896 and occurs within a region of CNR1 intron 2 that has been conserved for 310
million years. A, a 17-species vertebrate alignment plot from the UCSC Genome Browser highlights the presence of a putative enhancer region conserved
between birds and humans. Thewhite line represents the location of rs944458within this sequence. The top scale bar represents linear distance (2 kb), and the
second scale bar represents coordinates inbasepairs along the lengthofhumanchromosome6.B, an LDheatmapanalysis of SNPswithinCNR1 intron2derived
from theUCSCbrowser demonstrating levels of LD (r2) between the different SNPs. Thismap is in linear registerwith the graph inA. Exactmeasurements of LD
(as calculated by SNAP LD) are displayed as decimal fractions in the grey diamonds linking the three SNPs of interest (rs9444584, rs92023230, and rs9450896).
The location of rs9444584 is highlighted using a black box and line. The locations of rs92023230 and rs9450896 are highlighted using gray boxes.
FIGURE 2. rs9444584 allele frequency varies greatly in different humanpopulations and changes the predicted affinity of AP1 transcription factor.A,
pairwise alignment of the human and chicken ECR1 sequences showing predicted transcription factor binding sites and allelic variants of rs944458. AR,
androgen receptor; C/EBP, CCAAT enhancer-binding protein; TFII-A, transcription factor II A. B, table from the National Center for Biotechnology Information
(NCBI) SNP web site showing population diversity of rs944458 in European, Asian, and sub-Saharan African populations. C, table generated by the RegSNP
algorithm showing predicted relative binding affinities of each allele of rs944458 to the AP1 transcription factor. Matrix score and core score values represent
the probability that AP1 will bind to each allelic binding site. D, diagrammatic representation of each of the plasmid constructs used in the current study (not
to scale). Bent arrows represent the transcriptional start site of the luciferase gene. ss#, assigned submitter SNP ID, Chrm. Sample. Cnt, chromosome sample
count, IC, individual Genotype, and GF, genotype frequency.
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ECR1(C) Is Active within Primary Hypothalamic Cell Cul-
tures and DRG but Not in Primary Hippocampal Cells—Be-
cause CNR1 is expressed in many different parts of the brain
and peripheral nervous system such as the hypothalamus, hip-
pocampus, and DRG, we explored the hypothesis that the most
common allele, ECR1(C), acted as an enhancer of promoter
activity within cells derived from specific regions of the brain.
ECR1(C) was amplified using high fidelity PCR from human
placental DNA and cloned into the pTAL-Luc vector (Clon-
tech) that contains a TATA-like promoter (PTAL) region from
the herpes simplex virus-thymidine kinase promoter linked to a
luciferase reporter (Fig. 2D). This commercially available plas-
mid has been widely used to assay gene regulatory sequences in
the past andwill subsequently be referred to as pLuc. Because of
the known function of CB1 in the hypothalamus, DRG, and
hippocampus in appetite, cognition, and pain, respectively, we
examined whether the ECR1(C) acted as an enhancer of pro-
moter activity in primary cells derived from these different tis-
sues. We also chose to use primary lines as the activity of many
enhancer regions has been shown to be highly context-depen-
dent (19–20, 22, 23, 25, 28–30). pLuc and pECR1(C)weremag-
netofected into primary cell cultures derived from the hypo-
thalamus, hippocampus, or DRG, and after 24 h, Dual-
Luciferase assays were performed. It was observed that
ECR1(C) was able to act as an enhancer of promoter activity in
hypothalamic and DRG cells (Fig. 3, A and B) but not in hip-
pocampal cells (Fig. 3C).
ECR1(C) Enhancer Activity Is Responsive to MAP Kinase
Activation in Primary Hypothalamus- and DRG-derived Cells
but Not in Hippocampal Cells—Angiotensin II (angiotensin) is
a widely recognized inducer of many different MAP kinase
pathways at concentrations ranging from 500 nM to 10M (31–
33). We cultured different primary cells transfected with
pECR1(C) in the presence of angiotensin II and demonstrated
that ECR1(C) could respond to angiotensin in both primary
DRG and hypothalamic cells (Fig. 3, A and B). However, we
were unable to detect any significant up-regulation of ECR1(C)
in hippocampus-derived cells.
Response of ECR1(C) to Angiotensin in Hypothalamic Cells Is
Modulated by MEK Kinase and p38 Kinase Pathways—We
explored which of the three major MAP kinase pathways were
involved in mediating the effects of angiotensin on ECR1(C) by
culturing pECR1(C)-transfected hypothalamic cells in the pres-
ence of angiotensin and an antagonist specific for the MEK
kinase (U0216), JNK (SP6000125), or p38MAP (SB202190)
kinase pathways in hypothalamic cells. The JNK kinase inhibi-
tor had no significant effect on the ability of angiotensin to
induce the activity of ECR1(C) (Fig. 4B). However, incubation
with the p38 agonist halved the induction of ECR1(C) induced
by angiotensin, and treatment with the MEK kinase inhibitor
completely abolished the action of angiotensin (Fig. 4,A andC).
ECR1(T) Allele Demonstrates Significant Differences from
ECR1(C) as an Enhancer inHippocampal Cell Cultures—Using
bioinformatics, we predicted that ECR1(T) would bind the AP1
protein with a higher affinity (Fig. 2C). This is an interesting
prediction in the context ofMAP kinase signaling as AP1 activ-
ity is known to be modulated by MAP kinase pathways includ-
ing JNK andMEK kinase (34). We used site-directed mutagen-
esis of the pECR1(C) plasmid to produce pECR1(T) (Fig. 2D).
We compared pECR1(T) activity with that of pECR1(C) in
hypothalamic, DRG, or hippocampal cell cultures. ECR1(T)
demonstrated 50 and 40% higher enhancer activity in primary
cells derived from hypothalamus and DRGs, respectively, than
the ECR1(C) allele (Fig. 3, A and B). Significantly, and in strong
contrast to ECR1(C), it was observed that ECR1(T) demon-
strated potent enhancer activity in hippocampal neuronswhere
ECR1(C) was inactive (Fig. 3C).
ECR1(T) Demonstrates Significant Allele-specific Differences
from ECR1(C) in Its Response to Activation of MAP Kinases—
We have demonstrated that ECR1(C) responded to MAP
kinase activation in both hypothalamus-derived and DRG-de-
rived primary cultures but not in hippocampal cultures (Fig. 3,
FIGURE3.Allele-specific properties of ECR1 indifferentprimary cell types and following stimulationofMAPkinasepathways.A–F, graphs showing the
results of Dual-Luciferase analyses of primary cells derived from neonate rat hypothalamus (A and D), DRG (B and E), and hippocampus (C and F) following
transfection with the different constructs shown in Fig. 2D and treatment with angiotensin II for 24 h (D–F; 10 M). Cells were lysed, and relative luciferase
activity was determined and normalized to an internal Renilla luciferase control (pRL-CMV). ns not significant, *, p 0.05, **, p 0.01.
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D–F). However, in hippocampal cells treated with angiotensin,
and in direct contrast to ECR1(C), activity of ECR1(T) was
increased by over 300% when compared with the untreated
sample (Fig. 3F). Surprisingly, although activation of MAP
kinases in these hypothalamic cells increased the activity of
ECR1(C) by nearly 10-fold, application of angiotensin to hypo-
thalamic cultures transfected with pECR1(T) virtually inacti-
vated ECR1(T) activity in these cells (Fig. 3D). Similarly,
although treatment of DRG neurons with angiotensin
increased activity of ECR1(C), no significant increase in
ECR1(T) activity was observed (Fig. 3E).
DISCUSSION
Using a unique combination of in silico genetics, compara-
tive genomics, molecular biology, and primary cell culture, we
present evidence of a novel cis-regulatory region, ECR1(C), that
is active in hypothalamus- and DRG-derived cells where it is
responsive to MAP kinase signaling, but inactive in the hip-
pocampus. However, themost significant finding from the cur-
rent study is that, in contrast to ECR1(C) a second allele of
ECR1 present in the population, ECR1(T), acts as a potentMAP
kinase-inducible enhancer in hippocampus cells. These
intriguing observations may have important implications for
understanding disease because rs9444584 is in strong LD with
two other polymorphisms that have been previously linked to
diseases such as obesity, addiction, and reduced frontal brain
volumes in schizophrenia as a result of cannabis misuse.
We explored the possibility that MAP kinase pathways were
involved in controlling ECR1 as MAP kinase pathways in the
hypothalamus and DRG have been shown to play a role in the
modulation of appetite (35) and pain (36), processes in which
the CB1 receptor is also involved (3–5). Furthermore, CB1 acti-
vation is known to triggerMAP kinase pathways (37). Thus, it is
possible that one role for the ECR1(C) enhancer in the hypo-
thalamus would be to allow a response to MAP kinase path-
ways, triggered by CB1 activation, to modulate CB1 levels in
response to food availability. For example, MEK/ERK kinase
pathways are induced by activation of CB1 in N1E-115 neuro-
blastoma cells, supporting the existence of a CB1-MAP kinase
autocrine loop in certain groups of neurons (38). In keeping
with these studies, we were able to demonstrate that the MAP
kinase pathways responsible for the activity of ECR1(C) in
hypothalamic cells were primarily the MEK kinase pathways
with input from p38MAP kinases. These are interesting obser-
vations as the T allele of rs2023239, which is in strong LD with
rs9444584, has been associated with higher body mass index in
both Swiss obese subjects and Danish individuals (11). Consid-
ering the role of the CB1 gene in appetite in the hypothalamus
and the triggering ofMAP kinase signaling by CB1 activation, it
can be hypothesized that increased sensitivity of ECR1(T) to
MAP kinase signaling might play a role in perturbing CB1
expression in the hypothalamus, leading to changes in appetite
and increased body mass index.
Because our algorithm predicted that AP1 binding affinity
would be increased in ECR1(T), we were not surprised to
observe that it became more responsive to MAP kinase activa-
tion in hypothalamic cells. However, we were surprised to
observe such a clear difference in the ability of the ECR1(C) and
ECR1(T) alleles to activate promoter activity in hippocampal
cells. In addition, the ability of ECR1(T) to respond to MAP
kinase activation in hippocampal cells, in clear contrast to the
response of ECR1(C) in these cells, was also unexpected. These
may be important observations as MAP kinase signaling, in the
form of ERK-MEK kinase, in the hippocampus is involved in
CB1-mediated neurogenesis and the synaptic integrity required
for stable long termmemory formation and cognition (39–42).
In addition, changes in the structure of the hippocampus and
in plasticity of hippocampal neurons have been linked to can-
nabis-related psychosis (43–45). Intriguingly, rs94580898 is in
strong LD with rs9444584 and has been associated with reduc-
tions in white matter in schizophrenia patients following can-
nabis overuse (17). The heightened sensitivity of ECR1(T) to
MAP kinase signaling in the hippocampus in comparison with
ECR1(C) may represent a possible mechanisms to explain the
cognitive deficits and reduced white matter experienced by
many schizophrenia sufferers and heavy marijuana users.
Consistent with the results of the current study, previous
research has demonstrated that that CB1 receptor coupling to
G-proteins differs between different brain regions and there-
FIGURE4.ECR1(C)activity is controlledbyMEK/p38kinasesignaling inhypothalamicneurons.Primary rathypothalamicneuronswerecultured for3days
and then transfectedwith apECR1(C) construct and treatedwith angiotensin II (AngII, 10M) in thepresence/absenceofMEK kinase inhibitor (U0216, 1M) (A),
JNK II inhibitor (SP600125, 50 nM) (B), or p38 kinase inhibitor (SB 202190, 10M) (C). The control is the pECR1(C) construct treatedwith a respective vehicle. Cells
were incubated with treatment for 24 h and then assayed for luciferase activity. Cells were lysed, and a relative luciferase measurement was determined and
normalized to an internal Renilla luciferase control (pRL-CMV). ns not significant, *, p 0.05, **, p 0.01.
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fore depends on the cellular environment, i.e. it is context-de-
pendent. One possible mechanism governing this context
dependence is receptor coupling. For example, Breivogel et al.
(46) demonstrated that receptor coupling efficacy is relatively
higher in the hypothalamus than the hippocampus. From auto-
radiographic analysis, the relatively sparse cannabinoid recep-
tors in the hypothalamus appeared to activate nearly as many
G-proteins as in the receptor-dense hippocampus. These data
imply that theCB1 receptor-mediated initiation of downstream
signaling in the hypothalamus and hippocampus differ signifi-
cantly and may have consequences for the initiation of MEK-
mediated regulation of CNR1 expression in the hippocampus.
This is in line with our results demonstrating regional differ-
ence in control of CNR1 expression viaMAPK signaling. The
findings have far reaching implications for the effects of can-
nabis in the brain as studies have demonstrated that the
MEK pathway is implicated in regional differences in the
development of tolerance to 9THC, the major psychoactive
constitute of cannabis (47). Furthermore, cannabis smoking
in adolescence is associated with an increased risk of psycho-
sis, particularly in individuals with a family history of schiz-
ophrenia (48). Studies reveal that CB1 receptors in adoles-
cent hippocampus have lower functional coupling to
G-proteins and desensitize more slowly in response to THC
treatment than those of adults (49). It could be speculated
that polymorphisms in ECR1 may increase susceptibility of
adults and adolescents to develop psychosis when exposed to
high potency cannabis.
Further evidence for the possible harmful effects of ECR1(T)
comes from the observation that following the migration of
Eurasian ancestors out of Africa and into the Middle East
40,000 years ago, ECR1(T) was clearly selected against within
these populations where the allelic frequency of ECR1(T) has
been reduced from50% inAfrican populations to as little as 13%
of the population in Europe and Asia. It may not be entirely
coincidental that this reduction in the frequency of ECR1(T)
occurred subsequent to the arrival of Eurasian ancestral popu-
lations in a region of the world where Cannabis sativa was
endemic and in which it had been used for religious, medicinal,
and recreational purposes for many thousands of years (50).
Further support for this hypothesis comes from a number of
studies that have reported a higher incidence of psychosis in
individuals of African and Caribbean origin (21, 51–53),
although the role of cannabis use in these studies was not fully
explored.
Apossiblemechanismcanbe inferred ifwe consider thatCB1
activation is known to trigger MAP kinase pathways (37) in
neuronal cells and that the ECR1(T) allele responds more
strongly to MAP kinase activation in hippocampal cells, where
the ECR1(C) allele does not. Thus the current study raises the
possibility of the presence of a potentially harmful CB1-MAP
kinase-ECR1(T) autoregulatory loop in hippocampal neurons
in a proportion of the human population that contributes to
susceptibility to many of the conditions associated with
rs9450898 and rs2023239 or the negative effects of high
potency cannabis use.
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